Biotech Values

[biocqr]

DCPH > up 5% on Phase I interim data...

Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
https://finance.yahoo.com/news/deciphera-pharmaceuticals-reports-data-ongoing-120000807.html

The poster, titled “DCC-2618, a novel pan-KIT and PDGFRa kinase switch control inhibitor, shows encouraging signal in a patient with glioblastoma (GBM)”, was presented by Professor John de Groot, Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. Of the eight patients diagnosed with malignant gliomas treated with DCC-2618, five patients were evaluable, and four of those patients had GBM. The data showed:

Out of the four evaluable GBM patients, DCC-2618 achieved an encouraging partial response in one patient with triple amplification of PDGFRa, KIT and VEGFR-2 (4q12 amplicon) with a 94% tumor reduction per RANO after 84 weeks (cycle 23, day 1).

Across the safety population studied (n=70), as of the data cut-off of July 28, 2017, DCC-2618 was generally well-tolerated at all dose levels evaluated and three DLT events were determined to be not clinically significant (two G3 lipase elevations and one G4 CPK elevation). An expansion cohort of the Phase 1 clinical trial is now open to facilitate further evaluation in this patient population.

poster...
https://docs.google.com/viewer?url=https%3A%2F%2Fwww.deciphera.com%2Fwp-content%2Fuploads%2F2017%2F11%2FSNO-2017-DeGroot-et-al-DCC-2618-Glioma-v11-002.pdf